A case of immune-mediated PRCA, among multiple immune adverse events, following treatment with a check-point inhibitor (anti-CTLA-4) has also been reported.32 In our patient, we utilized IL-2 to activate an anticancer cellular immune response and obtained a broad activation of immunity, leading to PRCA (she meets all diagnostic criteria). This evidence concerns the gene IL2 and pure red-cell aplasia.